Social Media Sidebar


Please sign up, comment on articles and bring your friends!

Current poll

PlanetTech is asking:

What do you think about our new web site?

Love it, indeed
Really good solution
Same as old one
The old one was better
This is a new option

Quote of the day

Just because something doesn’t do what you planned it to do doesn’t mean it’s useless.


Thomas Edison

Vaccine that targets Alzheimers protein, human trials in two to three years

Posted in Science on 15th Jul, 2016 07:41 PM by AlexMuller

Researchers have made an Alzheimer’s breakthrough that may result in world’s first dementia vaccine. Developed by Australian and US scientists, this vaccine may not only prevent but also reverse early stages of Alzheimer’s, the most common form of dementia.

The Alzheimer’s vaccine may be tested on humans within the next two to three years with US Government funding. Scientists from Flinders University and America’s Institute of Molecular Medicine and University of California developed the vaccine by targeting proteins in the brain that block neurons.
The formula targets tau proteins and abnormal beta-amyloid that cause Alzheimer’s. The scientists are confident that the vaccine would eventually be used as preventative vaccine. According to Flinders University medicine professor Nikolai Petrovsky, the proteins must be removed from the brain as Alzheimer’s, and dementia sufferers have lots of these broken down proteins inside.
The World Health Organisation (WHO) has projected a US$600 billion (AU$790 billion) cost per year as total global societal cost of dementia-related illnesses and care. The WHO also noted there are 7.7 million new cases every year.
The first protein “to go wrong” was a-beta. However, targeting the second protein tau actually helped reverse the progression. Targeting the tau protein with the vaccine you can actually reverse the disease even once it has developed
Nature Scientific Reports - Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
Although β-amyloid (Aβ) may be the primary driver of Alzheimer’s disease (AD) pathology, accumulation of pathological tau correlates with dementia in AD patients. Thus, the prevention/inhibition of AD may require vaccine/s targeting Aβ and tau simultaneously or sequentially.
Since high antibody titers are required for AD vaccine efficacy, we have decided to generate vaccines, targeting Aβ (AV-1959R), Tau (AV-1980R) or Aβ/tau (AV-1953R) B cell epitopes, based on immunogenic MultiTEP platform and evaluate the immunogenicity of these vaccines formulated with AdvaxCpG, delta inulin, Alhydrogel®, Montanide-ISA51, Montanide-ISA720, MPLA-SM pharmaceutical grade adjuvants. Formulation of AV-1959R in AdvaxCpG induced the highest cellular and humoral immune responses in mice.
The dual-epitope vaccine, AV-1953R, or the combination of AV-1959R and AV-1980R vaccines formulated with AdvaxCpG induced robust antibody responses against various forms of both, Aβ and tau pathological molecules. While anti-Aβ antibody titers after AV-1953R immunization were similar to that in mice vaccinated with AV-1959R or AV-1959R/AV-1980R combination, anti-tau titers were significantly lower after AV-1953R injection when compared to the AV-1980R or AV-1959R/AV-1980R.
In silico 3D-modeling provided insight into the differences in immunogenicity of these vaccine constructs. In sum, AV-1959R and AV-1980R formulated with AdvaxCpG adjuvant were identified as promising immunogenic vaccines for ongoing pre-clinical assessment and future human clinical trials.
Aβ-mediated plaque formation is thought to be the primary event in Alzheimer’s disease (AD) pathogenesis. Later, AD pathology becomes self-propagating with less dependence on Aβ and greater involvement of other proteins such as tau. The temporal relationship of misfolded proteins in AD pathogenesis may have relevance to AD vaccine strategies.
Hence, vaccines targeting Aβ only may be effective prior to or in the very early stages of AD pathogenesis, whereas vaccines targeting tau may remain effective in latter stages of AD. Therefore, the most effective strategy may be to develop an immunogenic vaccine or vaccines targeting both Aβ and tau, such that the same vaccine or the combination of vaccines would then be effective across the entire spectra of AD progression.

Tags: brainAlzheimer'sdementiaresearchhealthmedicine

Read original article » Back to category


Author: Guest
Posted: 2016-07-16
It is great that the scientists are confident that the vaccine would eventually be used as preventative vaccine. This would also require an early, accurate diagnostic test
1 Replies
Author: Guest
Posted: 2016-07-16
Unless is so affordable that everyone over 60 can be vaccinated .... Reply
Author: Guest
Posted: 2016-07-21
Th3t#&a9;s not a lot of sleep, I can understand you're tired. Take it easy, one step at a time and you will do fine and leave the snacking behind. Have fun at the run tonight and I hope you have a good night sleep too. Reply


Recent headlines

  • Posted in Business on 2018-05-21 16:28:10
    Anti-nuclear policies increased global carbon by more
    Posted in Medicine on 2018-05-21 16:22:31
    Magic mushroom treatment improves emotional more
    Posted in Medicine on 2018-05-21 16:18:57
    Antioxidant found to wind back the clock on blood more
    Posted in Software on 2018-05-21 16:14:32
    3 key artificial intelligence benefits for the future more
    Posted in Medicine on 2018-05-20 11:05:43
    Cannabidiol significantly reduces seizures in more
Posted in Business on 2013-10-10 01:33
China is working towards a manned lunar mission in more
Posted in Business on 2013-10-20 07:17
Spacex says China is their main competitor for more
Posted in Software on 2013-10-20 06:43
Pirate Bay Browser Clocks 1,000,000 more
Posted in Medicine on 2013-10-10 02:10
Google reportedly investing hundreds of millions into more
Posted in Medicine on 2013-10-14 03:13
Endothelial Cells Can Repair and Regenerate Organs, more
Posted in Science on 01.01.2010
Spacex says China is their main competitor for more
Posted in Science on 01.01.2010
Staring at Your Phone Could Be Making You Short more
Posted in Science on 01.01.2010
Oculus Rift virtual reality headset coming to mobile, more
Posted in Science on 01.01.2010
China is working towards a manned lunar mission in more
Posted in Science on 01.01.2010
Delivering drugs via nanoparticles to target more

Recent Blog Posts

  • Posted by AlexMuller
    In five years quantum computing will be more
    Posted by AlexMuller
    Google partners with Johnson and Johnson to make lower more
    Posted by AlexMuller
    Electron holography microscope with spatial resolution down more
    Posted by AlexMuller
    Lower cost advanced Nuclear power could dominate future US more
    Posted by AlexMuller
    Why Hasn’t AI Mastered Language Translation? more

Login to your Account

Login to your PlanetTech Account here

Remember me

Create a New Account

You just need username and password

The following errors occured:
Verify password:
Remember me